

1 **Risk of heart disease following breast cancer: results from a population-based cohort**
2 **study**

3 Haomin Yang, PhD^{1,2}, Nirmala Bhoo-Pathy, PhD³, Judith S. Brand, PhD⁴, Elham Hedayati,
4 PhD⁵, Felix Grassmann, PhD^{2,6}, Erwei Zeng, MSc², Jonas Bergh, PhD^{5,7,8}, Weiwei Bian,
5 MSc², Jonas F. Ludvigsson, PhD^{2,9}, Per Hall, PhD^{2,10}, Kamila Czene, PhD²

6 **Author affiliations:**

- 7 1. Department of Epidemiology and Health Statistics, School of Public Health, Fujian
8 Medical University, 350122, Fuzhou, China
- 9 2. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels
10 Väg 12A, 171 77 Stockholm, Sweden.
- 11 3. Centre for Epidemiology and Evidence-Based Practice, Faculty of Medicine, University
12 of Malaya, 50603 Lembah Pantai, Kuala Lumpur, Malaysia.
- 13 4. Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro
14 University, 70185, Örebro, Sweden.
- 15 5. Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- 16 6. Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
- 17 7. Breast Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
- 18 8. Karolinska Comprehensive Cancer Center, Stockholm, Sweden
- 19 9. Department of Pediatrics, Örebro University Hospital, 70185 Örebro, Sweden
- 20 10. Department of Oncology, South General Hospital, 118 83 Stockholm, Sweden

21 ***Corresponding author:**

22 Haomin Yang, PhD. Email: haomin.yang@ki.se; Phone: 0086-13581540402; Fax: 0086-591-
23 22862510. Department of Epidemiology and Health Statistics, School of Public Health, Fujian
24 Medical University, Xuefu North Road 1, University Town, Fuzhou, China.

25

26 **Tables: 3; Figures: 1; Supplementary Tables: 4**

27 **References: 44**

28 **Word count:2744**

29 **Running title:** Risk of heart diseases following breast cancer

30

31 **LIST OF ABBREVIATIONS**

32 ICD: International Classification of Diseases

33 CI: confidence intervals

34 HR: hazard ratio

35 CCI: Charlson Comorbidity Index

36

37 **ABSTRACT**

38 **BACKGROUND:** There is a rising concern about treatment-associated cardiotoxicities in breast
39 cancer patients.

40 **OBJECTIVES:** This study aimed to determine the time- and treatment-specific incidence of
41 arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer.

42 **METHODS:** A register-based matched cohort study was conducted including 8338 breast cancer
43 patients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017.
44 Overall and time dependent risks of arrhythmia, ischemic heart disease and heart failure in breast
45 cancer patients were assessed using flexible parametric models as compared to matched controls
46 from general population. Treatment-specific effects were estimated in breast cancer patients using
47 Cox model.

48 **RESULTS:** During a median follow-up of 10.8 years, the hazard ratios for arrhythmia, heart failure
49 and ischemic heart disease, were 1.27 (95% CI = 1.18-1.37), 1.38 (95% CI = 1.23-1.55), and 0.93
50 (95% CI = 0.84-1.03), respectively. Time-dependent analyses revealed long-term increased risks of
51 arrhythmia, and heart failure in breast cancer patients compared to matched controls. The risk of
52 ischemic heart disease was only elevated in the first year after cancer diagnosis. Trastuzumab and
53 anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not
54 tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease
55 was identified following loco-regional radiotherapy.

56 **CONCLUSIONS:** Administration of systemic adjuvant therapies appear to be associated with
57 increased risks of heart disease. The risk estimates observed in this study may serve as reference to
58 aid adjuvant therapy decision-making and patient counseling in oncology practices.

59

60 INTRODUCTION

61 The use of adjuvant systemic therapies at least halves the risk of dying from breast cancer
62 (Early Breast Cancer Trialists' Collaborative, 2005, 2012; Early Breast Cancer Trialists'
63 Collaborative et al., 2015; Goldvaser et al., 2019; Gray et al., 2019). Nowadays, 80% of the
64 breast cancer patients survive for at least 10 years and many will become long-term survivors
65 (Colzani et al., 2011a). There are, however, concerns about therapy associated late adverse
66 health effects, including cardiovascular events (Khoury et al., 2012). Use of common (neo-)
67 adjuvant therapies for breast cancer have been associated with an increased risk of heart
68 diseases including heart failure, arrhythmias and ischemic heart disease (Darby et al., 2013;
69 Doyle, Neugut, Jacobson, Grann, & Hershman, 2005; Harris et al., 2006; Hooning et al., 2007;
70 Pinder, Duan, Goodwin, Hortobagyi, & Giordano, 2007; C. Taylor et al., 2017; Yeh &
71 Bickford, 2009). However, this evidence mostly comes from studies focusing on specific
72 subgroups of patients based on age, cancer stage or treatment regimen.

73 Although the benefits of radiotherapy far outweigh the risk of heart diseases, some studies
74 have found increased incidence of and mortality due to heart disease in women subjected to
75 modern doses of adjuvant radiotherapy (Darby et al., 2013; C. Taylor et al., 2017). Knowledge
76 on cardiotoxic effects of anthracycline-based chemotherapy regimens have led to lowering of
77 doses and less use of bolus injections to reduce peak concentrations of anthracyclines (Foukakis
78 et al., 2016), but it is estimated that the risk of heart failure associated with anthracyclines
79 remains increased for standard low-dose group as compared to non-users (Chung et al., 2020).
80 While trastuzumab has been shown to reduce the risk of breast cancer mortality at 11 years of
81 follow-up (Cameron et al., 2017), evidence on its cardiotoxicity is conflicting (Bowles et al.,
82 2012; Papakonstantinou et al., 2020). In addition, recent evidence suggests that use of aromatase
83 inhibitors in women with hormone receptor positive breast cancer may increase the risk of heart

84 failure, compared to tamoxifen (Khosrow-Khavar, Filion, Bouganim, Suissa, & Azoulay,
85 2020).

86 Risk assessment of immediate and later occurring heart disease events following breast
87 cancer is important for the planning of cardiac surveillance programs and possible prophylactic
88 pharmacotherapy. Here, we report the risks of heart diseases in in a cohort representative of the
89 general breast cancer population with long-term follow-up. We specifically aimed to assess
90 risks of heart diseases by time since diagnosis, and according to adjuvant treatments.

91 **Materials and Methods**

92 Breast cancer cohort

93 This study took advantage of the Stockholm-Gotland Breast Cancer Register comprising all
94 women diagnosed with primary invasive breast cancer between 2001 and 2008 in the Stockholm-
95 Gotland region. The Stockholm-Gotland Breast Cancer Register has about 99% completeness and
96 provides detailed information on tumor and treatment characteristics, as well as routine follow-up
97 on locoregional recurrences and distant metastases (Colzani et al., 2011b; Wigertz et al., 2012). We
98 included all patients diagnosed with non-metastatic disease (stages I-III) at age 25 to 75 years (N =
99 8338). To compare the risk of heart diseases after breast cancer, we randomly sampled up to 10
100 women from the general female population in Stockholm-Gotland region matched on year of birth
101 and whether they had history of the three heart diseases (Supplementary Figure 1). We performed
102 the matching procedure for these three heart diseases separately. Each reference individual was alive
103 and free of breast cancer on the date of the matched patient's diagnosis of breast cancer (the index
104 date).

105 The matched cohort was linked through the unique personal identity number to the Swedish
106 Cancer Register, Patient Register, Cause of Death Register and Migration Register, and follow-up
107 started from the index date until the date of heart disease diagnosis, emigration, death, breast cancer
108 relapse or end of follow-up (31 December 2017), whichever occurred first. We also performed

109 linkage with the Prescribed Drug Register which contains data on all drugs dispensed from Swedish
110 pharmacies from July 2005 onward to validate the use of hormone therapy. Detailed description of
111 the breast cancer cohort can be found elsewhere (Holm et al., 2016).

112 The study was approved by the Regional Ethical Review Board in Stockholm.

113 Heart diseases

114 We identified the following heart diseases according to relevant ICD (International
115 Classification of Disease) codes in the Swedish Patient Register and the Cause of Death
116 Register (Supplementary Table 1): heart failure (ICD-10: I50, ICD-9: 428A, 428B, 428X),
117 arrhythmias (ICD-10: I47-I49, ICD-9: 427), and ischemic heart disease (ICD-10: I20-I25, ICD-
118 9: 410-414). We included both inpatient and outpatient diagnoses, as well as cause of death
119 records in our outcome definition, except for myocardial infarction, which was based on
120 inpatient and cause of death records solely. To ensure specificity of the outcomes studied, only
121 primary, and not underlying, diagnoses were considered for analyses.

122 Breast cancer treatment specifics

123 We extracted the treatment data from the Stockholm-Gotland Breast Cancer Register.
124 Because ~90% of HER-2 positive cancers were treated with trastuzumab between 2005 and
125 2008 in the Stockholm-Gotland region, HER-2 positivity was used as a proxy when no registry
126 data on trastuzumab was available during this time period. Data on adjuvant endocrine therapy
127 was verified against the Prescribed Drug Register and categorized into tamoxifen and / or
128 aromatase inhibitor (AI) use. Since radiotherapy to the left breast has, in particular, been
129 implicated in heart complications, radiotherapy was categorized according to tumor laterality
130 (left vs. right). Bilateral tumors were coded as receiving left-sided radiotherapy in this analysis.
131 Chemotherapy was coded as anthracycline-based, anthracycline plus taxane-based,
132 cyclophosphamide, methotrexate and fluorouracil (CMF)-based regimens, or
133 unknown/unspecified.

134 Covariates

135 The Stockholm Breast Cancer Register contains data on date of diagnosis, menopausal
136 status at diagnosis and type of surgery (breast conserving surgery vs. mastectomy). Tumor
137 characteristics were also retrieved from this register, including tumor size (T), regional lymph
138 node involvement (N) and presence of metastases (M), all from pathology records and
139 summarized in TNM stage as defined according to the American Joint Committee on Cancer
140 ("American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition. ,"). Information
141 on inpatient comorbidities at diagnosis was extracted though the Swedish Patient Register and
142 summarized into the Charlson Comorbidity Index (CCI) score, a widely used method for
143 classifying chronic comorbid conditions (Charlson, Pompei, Ales, & MacKenzie, 1987). To
144 account for the potential confounding effect from tobacco abuse, chronic pulmonary disease,
145 and hypertension in the associations, we further identified associated diagnoses before cancer
146 using ICD codes from the patient register. (Supplementary Table 1)

147 Statistical analyses

148 We compared the risk of heart diseases in breast cancer patients with that observed in the
149 matched cohort, using flexible parametric model (FPM), overall and stratified by history of
150 respective heart disease and time since diagnosis. We further plotted time-dependent hazard
151 ratios using FPM. The FPM is similar to the Cox proportional hazards model in that it provides
152 a HR as measure of association. The key advantage of FPM is that non-proportional hazards
153 can easily be fitted by adding a spline for the interaction with time. Kaplan-Meier curves were
154 used to assess the cumulative incidences of heart diseases in breast cancer patients and matched
155 reference individuals.

156 Next, we studied the association of adjuvant breast cancer therapy with heart disease risk
157 in breast cancer patients using Cox proportional hazards models. We adjusted these analyses
158 for age and year of diagnosis (model 1), and additionally for menopausal status at diagnosis,

159 cancer stage, type of surgery, CCI score, history of heart disease, hypertension, chronic
160 pulmonary disease and tobacco abuse. All treatment specific models were mutually adjusted
161 for adjuvant therapies. Taking the possible selection bias in administration of radiotherapy into
162 consideration, the analysis for radiotherapy only included patients receiving radiotherapy,
163 making a comparison between left-sided and right-sided breast cancer (Wadsten et al., 2018).
164 Missing indicators were included for the analysis of these covariates in the model. To
165 investigate the robustness of treatment specific associations, a sensitivity analysis was
166 performed excluding breast cancer patients with a history of heart disease. To explore the
167 potential time dependent effect of treatment, we separated the analysis according to different
168 follow-up periods, within 10 years after breast cancer diagnosis and beyond, respectively.

169 All statistical analyses were performed using STATA version 15.1.

170 **RESULTS**

171 Descriptive characteristics of the study population are described in Table 1. The median
172 age at breast cancer diagnosis was 59 years, with 75% of patients aged less than 65 years (Table
173 1). Approximately 40% of all patients received adjuvant chemotherapy, with anthracycline-
174 based regimens being most frequently administered. Endocrine therapy was received by more
175 than 80% of patients (constituting mainly of tamoxifen). Of all patients diagnosed between mid-
176 2005 and 2008, 13% were coded as receivers of trastuzumab.

177 Over a median follow-up of 10.8 years (interquartile range = 6.5 years) arrhythmias were
178 the most frequently reported heart disease (n = 677), followed by ischemic heart disease (n =
179 384) and heart failure (n = 306). The cumulative incidence of arrhythmias, ischemic heart
180 disease and heart failure in the cohort was 12.10%, 6.55% and 5.59% after 15 years of follow-
181 up, respectively (Supplementary Figure 2 and Supplementary Table 2).

182

183

184 **Table 1.** Descriptive characteristics of the study population.
185

Characteristics	overall (N = 8338)
Year of diagnosis. % (N)	
2001-2002	25.8 (2148)
2003-2004	24.3 (2027)
2005-2006	25.8 (2147)
2007-2008	24.2 (2016)
Age at diagnosis. % (N)	
< 50 years	22.3 (1857)
50-65 years	50.8 (4239)
>65 years	26.9 (2242)
Menopausal status. % (N)	
Premenopausal	29.4 (2311)
Postmenopausal	70.6 (5539)
Missing (N)	488
Stage. % (N)	
Stage I	48.1 (3826)
Stage II	39.4 (3131)
Stage III	12.5 (996)
Missing (N)	385
Comorbidity. % (N)	
None	88.6 (7385)
1	6.2 (514)
≥ 2	5.3 (439)
History of Arrhythmia. % (N)	
No	97.9 (8161)
Yes	2.1 (177)
History of Heart Failure. % (N)	
No	99.5 (8295)
Yes	0.5 (43)
History of Ischemic Heart Disease. % (N)	
No	98.1 (8176)
Yes	1.9 (162)
Surgery. % (N)	
No	1.1 (90)
Yes, breast-conserving	60.3 (5014)
Yes, mastectomy	38.6 (3205)
Missing (N)	29
Radiotherapy. % (N)	
No, right-sided	11.4 (928)
No, left-sided	11.8 (954)
Yes, right-sided	37.7 (3057)
Yes, left-sided	39.1 (3173)
Missing (N)	226
Chemotherapy. % (N)	
No	59.1 (4830)
Yes	40.9 (3343)
Missing (N)	165
Hormone therapy. % (N)	
No	18.0 (1472)
Yes, tamoxifen	53.6 (4380)
Yes, aromatase inhibitors	20.3 (1657)
Yes, type unknown	8.1 (664)
Missing (N)	165
Trastuzumab therapy, % (N) *	
No	87.6 (2277)
Yes	12.4 (323)
Missing (N)	1565

186 Missingness on individual variables is less than 5%, except for menopausal status (5.9%, N = 488). Treatment-specific analysis of trastuzumab
187 was restricted to patients diagnosed between 2005 and 2008 (missingness = 37.6%, N = 1565).


188 Overall, breast cancer patients experienced a 27% increased risk (HR = 1.27; 95% CI =
 189 1.18-1.37) of developing arrhythmia, and a 38% increased risk of heart failure (HR=1.38; 95%
 190 CI = 1.23-1.55) compared to matched reference individuals from general population, while the
 191 risk of ischemic heart disease was not increased (HR = 0.93; 95% CI = 0.84-1.03) (Table 2).
 192 Hazard ratios of for arrhythmias, ischemic heart disease and heart failure were not notably
 193 different in women with or without a previous diagnosis of these respective heart diseases.

194 Analyses by time since diagnosis revealed a short-term increase in risks of arrhythmia and
 195 heart failure (Table 2). An elevated risk of ischemic heart disease was observed in the first year
 196 after diagnosis (HR = 1.48; 95% CI = 1.14-1.91), followed by a decline with increasing follow-
 197 up time. Interestingly, increased risks for arrhythmia and heart failure were noted beyond 10
 198 years (Table 2, Figure 1).

199
 200 **Table 2.** Hazard for heart diseases in breast cancer patients compared to the matched cohort.
 201

	Arrhythmia		Heart Failure		Ischemic Heart Disease	
	No.	HR (95% CI)	No.	HR (95% CI)	No.	HR (95% CI)
Overall	677	1.27 (1.18-1.37)	306	1.38 (1.23-1.55)	384	0.93 (0.84-1.03)
Corresponding disease history						
No	585	1.28 (1.18-1.39)	286	1.39 (1.23-1.57)	321	0.91 (0.81-1.01)
Yes	92	1.30 (1.04-1.61)	20	1.25 (0.77-2.05)	63	1.04 (0.80-1.36)
Time since diagnosis						
<1 year	109	2.21 (1.81-2.70)	37	2.71 (1.88-3.91)	65	1.48 (1.14-1.91)
1-2 years	48	1.10 (0.82-1.48)	24	1.94 (1.26-3.01)	41	0.97 (0.70-1.34)
2-5 years	123	1.03 (0.86-1.24)	52	1.31 (0.99-1.74)	94	0.92 (0.75-1.13)
5-10 years	226	1.13 (0.99-1.30)	95	1.13 (0.91-1.38)	121	0.84 (0.70-1.00)
10-17 years	171	1.42 (1.22-1.66)	98	1.38 (1.12-1.69)	63	0.79 (0.61-1.01)

202
 203 * Abbreviations: No.=number of cases. HR=hazard ratio. CI = confidence interval. The HRs are estimated using
 204 flexible parametric model and conditioned on matching criteria (year of birth and history of respective heart
 205 disease). In all models, time since index date was the underlying time scale and a restricted cubic spline with four
 206 internal and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the
 207 baseline hazard.



210
211 **Figure 1.** Time dependent hazard ratio of heart diseases in breast cancer patients comparing to
212 age-matched women.

213 In all models, time since index date was the underlying time scale and a restricted cubic spline with four internal
214 and two boundary knots (five degrees of freedom) placed at quintiles of the event times, was used for the baseline
215 hazard. Time-dependent effects were modelled by adding interaction terms with time using a second spline with
216 three degrees of freedom.

217
218 Patients treated with chemotherapy and trastuzumab had an increased risk of heart failure
219 compared to patients not receiving these treatments (for patients receiving anthracyclines-based
220 chemotherapy, HR=1.99, 95% CI=1.38-2.85; for patients receiving trastuzumab, HR=2.04,
221 95%CI=1.10-3.80) (Table 3). The risk of heart failure in patients receiving anthracyclines ever
222 persisted for 10 years beyond the diagnosis of breast cancer (HR= 2.31, 95%CI=1.21-4.43,
223 supplementary table 3). Receipt of aromatase inhibitors was marginally associated with risk of
224 ischemic heart disease (HR=1.42, 95%CI=1.00-2.01 compared to patients without hormonal
225 therapy), but not with risk of heart failure or arrhythmias (Table 3). A direct comparison
226 between left-sided and right-sided radiotherapy, showed no evidence of an association of
227 radiotherapy with heart disease except for a somewhat increased risk of ischemic heart disease
228 in women with left sided breast cancer, particularly after 10 years after cancer diagnosis,
229 although not statistically significant (HR= 1.14, 95%CI=0.89-1.46; HR for the risk beyond 10
230 years=1.32, 95%CI=0.74-2.36). Sensitivity analyses excluding breast cancer patients with a
231 previous history of heart disease only slightly changed the point estimates of the treatment
232 effects but not the inferences (Supplementary Table 4).

233

Table 3. Hazard ratios for heart diseases by different adjuvant therapies

Treatment variables	Total No.	HR (95% CI) for Arrhythmia			HR (95% CI) for heart failure			HR (95% CI) for ischemic heart disease		
		N	Model1	Model2	N	Model1	Model2	N	Model 1	Model2
Radiotherapy										
Right-sided	3057	251	REF (1.00)	REF (1.00)	102	REF (1.00)	REF (1.00)	121	REF (1.00)	REF (1.00)
Left-sided	3173	244	0.93 (0.78-1.11)	0.91 (0.76-1.08)	104	0.96 (0.73-1.26)	0.99 (0.76-1.31)	141	1.11 (0.87-1.42)	1.14 (0.89-1.46)
Missing	226	13	-	-	14	-	-	9	-	-
Chemotherapy										
No	4830	454	REF (1.00)	REF (1.00)	176	REF (1.00)	REF (1.00)	262	REF (1.00)	REF (1.00)
Anthracyclines-based	1458	96	1.12 (0.90-1.41)	0.99 (0.77-1.28)	58	2.26 (1.66-3.08)	1.99 (1.38-2.85)	50	1.11 (0.81-1.52)	1.10 (0.78-1.57)
Anthracyclines+Taxanes	295	10	0.88 (0.47-1.67)	0.75 (0.39-1.45)	13	5.55 (3.05-10.08)	4.39 (2.31-8.37)	7	1.31 (0.60-2.82)	1.20 (0.54-2.67)
CMF	108	13	1.62 (0.93-2.82)	1.39 (0.79-2.47)	5	1.57 (0.64-3.84)	1.12 (0.45-2.79)	5	1.01 (0.41-2.45)	0.69 (0.28-1.70)
Type unknown	1482	93	1.21 (0.96-1.53)	1.15 (0.87-1.51)	43	1.87 (1.32-2.66)	1.65 (1.09-2.49)	55	1.38 (1.02-1.87)	1.44 (1.01-2.07)
Missing	165	11	-	-	11	-	-	5	-	-
Hormone therapy										
No	1472	101	REF (1.00)	REF (1.00)	55	REF (1.00)	REF (1.00)	57	REF (1.00)	REF (1.00)
Tamoxifen	4380	345	0.94 (0.75-1.17)	1.03 (0.81-1.31)	125	0.61 (0.45-0.84)	0.84 (0.60-1.18)	168	0.79 (0.58-1.07)	0.90 (0.65-1.24)
Aromatase inhibitors	1657	159	1.16 (0.90-1.51)	1.09 (0.83-1.43)	82	1.13 (0.79-1.62)	1.08 (0.74-1.57)	109	1.41 (1.00-1.97)	1.42 (1.00-2.01)
Type unknown	664	61	0.85 (0.61-1.19)	0.91 (0.65-1.28)	33	0.72 (0.46-1.13)	0.95 (0.59-1.51)	45	1.05 (0.70-1.58)	1.25 (0.82-1.89)
Missing	165	11	-	-	11	-	-	5	-	-
Trastuzumab *										
No	2277	160	REF (1.00)	REF (1.00)	52	REF (1.00)	REF (1.00)	81	REF (1.00)	REF (1.00)
Yes	323	21	1.17 (0.74-1.84)	1.42 (0.87-2.31)	15	2.69 (1.51-4.80)	2.04 (1.10-3.80)	15	1.63 (0.94-2.83)	1.48 (0.82-2.67)
Missing	1565	115	-	-	53	-	-	63	-	-

234

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model 1 are adjusted for age and calendar period. Hazard ratios for model 2 are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, ≥ 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

240

241

242

243

244

245 **DISCUSSION**

246 In a population-based setting, we demonstrated that the incidence of heart disease in breast
247 cancer patients was significantly higher than the incidence observed in matched reference
248 individuals from the general population. The risks of arrhythmia and heart failure were
249 increased even beyond 15 years after diagnosis. Receipt of trastuzumab, as well as
250 administration of anthracycline +/- taxane-based regimens were independently associated with
251 an increased risk of heart failure, while aromatase inhibitor therapy was associated with an
252 increased risk of ischemic heart disease.

253 We found an increased risk of arrhythmia and heart failure in breast cancer patients as
254 compared with the matched reference individuals from the general population, which is similar
255 to the risk of heart failure reported by a previous Dutch study (Hooning et al., 2007), indicating
256 the generalizability of our findings within European countries. In the present study, we further
257 found similar magnitude HRs estimates in patients with and without a previous diagnosis of
258 heart disease, suggesting no effect modification by disease history.

259 Analysis by time since diagnosis from the current study revealed long-term increased risks
260 of arrhythmia and heart failure following breast cancer. The long-term increased risk of heart
261 failure potentially reflects the profound cardiotoxic effect of anthracyclines, as we found
262 increased risk of heart failure in patients treated with anthracyclines beyond 10 years after
263 cancer diagnosis. As the long-term risk was observed for heart failure but not ischemic heart
264 disease, we hypothesized that the cardiotoxic effect of chemotherapy was mainly on the
265 myocardium but not the cardiac vessels. The finding that risk of ischemic heart disease in breast
266 cancer patients may be shortly elevated after diagnosis, but diminish over time is not
267 unexpected, considering the emotional distress of dealing with a new cancer diagnosis in the
268 patients, which may lead to higher short-term rates of ischemic heart disease (Fang et al., 2012;
269 Schoormans, Pedersen, Dalton, Rottmann, & van de Poll-Franse, 2016).

270 The findings that administration of anthracycline +/- taxanes, as well as trastuzumab are
271 associated with increased risks of heart failure are in agreement with previous observational
272 studies (Bowles et al., 2012; Chavez-MacGregor et al., 2013; Doyle et al., 2005; Du et al., 2009;
273 Goldhar et al., 2016; Thavendiranathan et al., 2016) and clinical trials (Chen et al., 2011) in
274 specific subgroups of breast cancer patients. While (poly)chemotherapy is thought to lead to
275 heart failure through a plethora of mechanisms that damage cardiomyocytes (Yeh & Bickford,
276 2009), taxanes may also interrupt the metabolism and excretion of anthracyclines, hence
277 accentuating their toxicity (Bird & Swain, 2008). Inhibition of the HER2 receptors in myocytes,
278 which regulates cell development and growth may largely explain the cardiotoxicity caused by
279 trastuzumab (Yeh & Bickford, 2009).

280 Population-based estimates of incidence of ischemic heart disease following treatment with
281 aromatase inhibitors have not been extensively reported in the literature (Matthews et al., 2018).
282 Abdel-Qadir, *et al* also found an increased risk of myocardial infarction in patients treated with
283 aromatase inhibitors, as compared to those treated with tamoxifen (Abdel-Qadir et al., 2016).
284 It has been posited that this apparent increase in risk of ischemic heart disease might in fact be
285 attributed to reduced risk of heart disease following tamoxifen treatment (Hackshaw et al.,
286 2011; Rosell et al., 2013). Nonetheless, given that in the present study, an increased risk of
287 ischemic heart disease was observed in patients treated with aromatase inhibitors compared to
288 patients not receiving hormone treatment, prior hypothesis that this observation is explained by
289 the protective effect of tamoxifen is not fully correct.

290 While several previous studies have shown that radiotherapy for breast cancer increase the
291 risk of ischemic heart disease and heart failure (Darby et al., 2013; Harris et al., 2006; Pinder
292 et al., 2007), some studies, particularly those including patients diagnosed in recent decades,
293 have not seen such increase (Boekel et al., 2014; Wadsten et al., 2018; Wennstig et al., 2020).
294 Indeed, the time trends of heart dose improvement and the use of modern heart dose sparing

295 techniques, together with individualized doses of therapy, may result in lower doses of radiation
296 to the heart (C. Taylor et al., 2017; C. W. Taylor & Kirby, 2015; C. W. Taylor et al., 2009).
297 Another reason for inconsistent results in the literature could be that patients with a left sided
298 breast cancer who are susceptible to cardiovascular disease are less likely to be selected for
299 radiotherapy (C. W. Taylor & Kirby, 2015). Therefore, in our study, we compared risk of
300 ischemic heart disease in patients treated with radiotherapy for left-sided to those treated for
301 right-sided breast cancer. We found slightly increased non-significant risk of ischemic heart
302 disease, this risk appeared (as expected) more pronounced in the follow-up period after 10
303 years. Overall, our results indicate only small risk of heart disease due to radiotherapy in women
304 treated in Sweden after year 2000.

305 A major strength of our study is that we were able to investigate risks of heart disease by
306 time since diagnosis and adjuvant treatment. The risk estimates presented in this study therefore
307 provide an insight into the short-term and long-term unintended effects of adjuvant breast
308 cancer therapy in routine clinical practice. Notably, all breast cancer patients were followed-up
309 for a relatively long period. The population-based nature of the study and linkage to registry-
310 based data further minimized the risk of selection and information biases.

311 We acknowledge several limitations. The Swedish Patient Register has high validity for
312 heart failure, arrhythmia and ischemic heart disease (with positive predictive value between
313 88%-98%) (Hammar et al., 2001; Ludvigsson et al., 2011), but some misclassification of heart
314 diseases may have occurred. We further tried to reduce the likelihood of misclassification by
315 analysing main diagnoses only. Secondly, we did not have complete data on trastuzumab during
316 the study period and relied on HER-2 status as proxy, which may have resulted in some
317 misclassification. The numbers of heart disease after trastuzumab and taxane were also
318 relatively small in our study, and might have resulted in limited power or chance finding when
319 identifying an association between trastuzumab/taxane and the relevant cardiac events. Besides,

320 the Stockholm-Gotland Breast Cancer Register only records intended treatment with
321 radiotherapy and chemotherapy, not whether patients were actually administrated with these
322 therapies. Finally, it should be noted that cancer patients are subject to increased medical
323 surveillance, especially in the initial period after diagnosis. This could explain the increased
324 rates of heart disease events especially within the first year of follow-up, although psychological
325 distress following recent diagnosis with cancer represents an alternative plausible explanation
326 for this observation (Fang et al., 2012; Schoormans et al., 2016).

327

328 Through this study, we demonstrate that compared to the general population, women with
329 breast cancer are associated with significantly increased risks of cardiovascular events
330 including heart failure and arrhythmia. The short term risk of ischemic heart disease diminished
331 after 1 year post diagnosis. The increased risk of arrhythmia and heart failure however appears
332 to persist long-term, beyond the first decade after diagnosis. The risk estimates observed in this
333 study may serve as reference to aid adjuvant therapy decision-making and patient counselling
334 in oncology practices.

335

336 **DECLARATIONS:**

337 **Competing interests:** The authors declare no competing interest.

338 **Ethics approval and consent to participate**

339 The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2009/254-
340 31/4).

341 **Author contributions:**

342 HY had full access to all of the data in the study and takes responsibility for the integrity
343 of the data and the accuracy of the data analysis. KC, NBP and HY conceived and designed the

344 study. All authors acquired, analyzed, or interpreted the data. HY and NBP drafted the
345 manuscript. All authors critically revised the manuscript for important intellectual content. HY
346 performed the statistical analysis. KC, NBP and HY obtained the funding. All authors read and
347 approved the final manuscript.

348

349 **Funding**

350 This work was supported by the Swedish Research Council [grant no: 2018-02547]; Swedish
351 Cancer Society [grant no: CAN-19-0266] and FORTE [grant no: 2016-00081]. HY was
352 supported by Startup Fund for high-level talents of Fujian Medical University [grant no:
353 XRCZX2020007] and Startup Fund for scientific research, Fujian Medical University [grant
354 no: 2019QH1002]. NBP was supported by the University of Malaya Impact-Oriented
355 Interdisciplinary Research Grant Programme [grant no: IIRG006C-19HWB]. WB was partly
356 supported by China Scholarship council. Dr Ludvigsson coordinates a study on behalf of the
357 Swedish IBD quality register (SWIBREG), which has received funding from Janssen
358 corporation. The funders had no role in the study design, data collection, analyses, data
359 interpretation, writing the manuscript, or in the decision to submit the manuscript for
360 publication.

361 **Acknowledgements**

362 Not applicable.

363 **Availability of data and materials**

364 The register-based cohort datasets linked and analyzed in the current study are not
365 publicly available due to Swedish law, but are available by applying through the Swedish
366 National Board of Health and Welfare and Statistics Sweden. Detailed information on data
367 application can be found using the following links [https://bestalladata.socialstyrelsen.se/data-](https://bestalladata.socialstyrelsen.se/data-for-forskning/)
368 [for-forskning/](https://bestalladata.socialstyrelsen.se/data-for-forskning/) and <https://www.scb.se/vara-tjanster/bestalla-mikrodata/>.

369 **Consent to publish**

370 All authors approved the manuscript and consented to its publication.

371 **Authors' information**

372 Not applicable.

373

374 **REFERENCES**

- 375 Abdel-Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., . . . Anderson, G. M. (2016).
376 The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-
377 menopausal women with early stage breast cancer. *European journal of cancer*, *68*, 11-21.
378 doi:10.1016/j.ejca.2016.08.022
- 379 American Joint Committee on Cancer. Breast Cancer Staging. 7th Edition. . Retrieved from Available
380 at <https://cancerstaging.org/references-tools/quickreferences/Documents/BreastLarge.pdf>
- 381 Bird, B. R., & Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: review of potential
382 cardiac problems. *Clin Cancer Res*, *14*(1), 14-24. Retrieved from
383 <https://www.ncbi.nlm.nih.gov/pubmed/18172247>. doi:10.1158/1078-0432.CCR-07-1033
- 384 Boekel, N. B., Schaapveld, M., Gietema, J. A., Rutgers, E. J., Versteegh, M. I., Visser, O., . . . van
385 Leeuwen, F. E. (2014). Cardiovascular morbidity and mortality after treatment for ductal
386 carcinoma in situ of the breast. *Journal of the National Cancer Institute*, *106*(8). Retrieved
387 from <https://www.ncbi.nlm.nih.gov/pubmed/25128694>. doi:10.1093/jnci/dju156
- 388 Bowles, E. J., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., . . .
389 Pharmacovigilance Study, T. (2012). Risk of heart failure in breast cancer patients after
390 anthracycline and trastuzumab treatment: a retrospective cohort study. *Journal of the*
391 *National Cancer Institute*, *104*(17), 1293-1305. Retrieved from
392 <https://www.ncbi.nlm.nih.gov/pubmed/22949432>. doi:10.1093/jnci/djs317
- 393 Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . . .
394 Herceptin Adjuvant Trial Study, T. (2017). 11 years' follow-up of trastuzumab after adjuvant
395 chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant
396 (HERA) trial. *Lancet*, *389*(10075), 1195-1205. Retrieved from
397 <https://www.ncbi.nlm.nih.gov/pubmed/28215665>. doi:10.1016/S0140-6736(16)32616-2
- 398 Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying
399 prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*,
400 *40*(5), 373-383. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/3558716>.
401 doi:10.1016/0021-9681(87)90171-8
- 402 Chavez-MacGregor, M., Zhang, N., Buchholz, T. A., Zhang, Y., Niu, J., Elting, L., . . . Giordano, S. H.
403 (2013). Trastuzumab-related cardiotoxicity among older patients with breast cancer. *Journal*
404 *of clinical oncology : official journal of the American Society of Clinical Oncology*, *31*(33),
405 4222-4228. Retrieved from <https://pubmed.ncbi.nlm.nih.gov/24127446>
406 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3821011/>. doi:10.1200/JCO.2013.48.7884
- 407 Chen, T., Xu, T., Li, Y., Liang, C., Chen, J., Lu, Y., . . . Wu, S. (2011). Risk of cardiac dysfunction with
408 trastuzumab in breast cancer patients: a meta-analysis. *Cancer Treat Rev*, *37*(4), 312-320.
409 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/20952131>.
410 doi:10.1016/j.ctrv.2010.09.001
- 411 Chung, I. Y., Lee, J. W., Moon, H.-G., Shin, K. H., Han, W., Son, B. H., . . . Noh, D.-Y. (2020). Effect of
412 standard low-dose anthracycline chemotherapy on late congestive heart failure in breast
413 cancer survivors aged between 50 and 59 at diagnosis: A nationwide study. *The Breast*, *53*,
414 125-129. Retrieved from

- 415 <http://www.sciencedirect.com/science/article/pii/S096097762030148X>.
416 doi:<https://doi.org/10.1016/j.breast.2020.07.006>
- 417 Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011a).
418 Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
419 age, and tumor characteristics. *Journal of clinical oncology : official journal of the American*
420 *Society of Clinical Oncology*, 29(30), 4014-4021. Retrieved from
421 <http://www.ncbi.nlm.nih.gov/pubmed/21911717>. doi:10.1200/JCO.2010.32.6462
- 422 Colzani, E., Liljegren, A., Johansson, A. L., Adolfsson, J., Hellborg, H., Hall, P. F., & Czene, K. (2011b).
423 Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis,
424 age, and tumor characteristics. *Journal of clinical oncology : official journal of the American*
425 *Society of Clinical Oncology*, 29(30), 4014-4021. Retrieved from
426 <http://www.ncbi.nlm.nih.gov/pubmed/21911717>
427 <http://jco.ascopubs.org/content/29/30/4014.full.pdf>. doi:10.1200/JCO.2010.32.6462
- 428 Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., . . . Hall, P.
429 (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J*
430 *Med*, 368(11), 987-998. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/23484825>.
431 doi:10.1056/NEJMoa1209825
- 432 Doyle, J. J., Neugut, A. I., Jacobson, J. S., Grann, V. R., & Hershman, D. L. (2005). Chemotherapy and
433 cardiotoxicity in older breast cancer patients: a population-based study. *Journal of clinical*
434 *oncology : official journal of the American Society of Clinical Oncology*, 23(34), 8597-8605.
435 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/16314622>.
436 doi:10.1200/JCO.2005.02.5841
- 437 Du, X. L., Xia, R., Liu, C. C., Cormier, J. N., Xing, Y., Hardy, D., . . . Burau, K. (2009). Cardiac toxicity
438 associated with anthracycline-containing chemotherapy in older women with breast cancer.
439 *Cancer*, 115(22), 5296-5308. Retrieved from
440 <https://www.ncbi.nlm.nih.gov/pubmed/19672997>. doi:10.1002/cncr.24621
- 441 Early Breast Cancer Trialists' Collaborative, G. (2005). Effects of chemotherapy and hormonal therapy
442 for early breast cancer on recurrence and 15-year survival: an overview of the randomised
443 trials. *Lancet*, 365(9472), 1687-1717. Retrieved from
444 <http://www.ncbi.nlm.nih.gov/pubmed/15894097>. doi:10.1016/S0140-6736(05)66544-0
- 445 Early Breast Cancer Trialists' Collaborative, G. (2012). Comparisons between different
446 polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome
447 among 100 000 women in 123 randomised trials. *The Lancet*, 379(9814), 432-444. Retrieved
448 from <http://www.sciencedirect.com/science/article/pii/S0140673611616255>.
449 doi:[https://doi.org/10.1016/S0140-6736\(11\)61625-5](https://doi.org/10.1016/S0140-6736(11)61625-5)
- 450 Early Breast Cancer Trialists' Collaborative, G., Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara,
451 T., . . . Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-
452 level meta-analysis of the randomised trials. *Lancet*, 386(10001), 1341-1352. Retrieved from
453 <http://www.ncbi.nlm.nih.gov/pubmed/26211827>
454 <http://spiral.imperial.ac.uk/bitstream/10044/1/32438/8/1-s2.0-S0140673615610741-main.pdf>.
455 doi:10.1016/S0140-6736(15)61074-1
- 456 Fang, F., Fall, K., Mittleman, M. A., Sparen, P., Ye, W., Adami, H. O., & Valdimarsdottir, U. (2012).
457 Suicide and cardiovascular death after a cancer diagnosis. *N Engl J Med*, 366(14), 1310-1318.
458 Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/22475594>
459 <http://www.nejm.org/doi/pdf/10.1056/NEJMoa1110307>. doi:10.1056/NEJMoa1110307
- 460 Foukakis, T., von Minckwitz, G., Bengtsson, N. O., Brandberg, Y., Wallberg, B., Fornander, T., . . .
461 Colorectal Cancer Study, G. (2016). Effect of Tailored Dose-Dense Chemotherapy vs Standard
462 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-
463 Risk Early Breast Cancer: A Randomized Clinical Trial. *JAMA*, 316(18), 1888-1896. Retrieved
464 from <https://www.ncbi.nlm.nih.gov/pubmed/27825007>. doi:10.1001/jama.2016.15865
- 465 Goldhar, H. A., Yan, A. T., Ko, D. T., Earle, C. C., Tomlinson, G. A., Trudeau, M. E., . . . Chan, K. K.
466 (2016). The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast

- 467 Cancer Patients: A Population Study. *Journal of the National Cancer Institute*, 108(1).
468 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/26476433>. doi:10.1093/jnci/djv301
- 469 Goldvaser, H., Korzets, Y., Shepshelovich, D., Yerushalmi, R., Sarfaty, M., Ribnikar, D., . . . Amir, E.
470 (2019). Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A
471 Systemic Review and Meta-Analysis. *JNCI cancer spectrum*, 3(2), pkz033-pkz033. Retrieved
472 from <https://pubmed.ncbi.nlm.nih.gov/31360906>
473 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649709/>. doi:10.1093/jncics/pkz033
- 474 Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., . . . Zambetti, M. (2019). Increasing the
475 dose intensity of chemotherapy by more frequent administration or sequential scheduling: a
476 patient-level meta-analysis of 37 298 women with early breast cancer in 26
477 randomised trials. *The Lancet*, 393(10179), 1440-1452. Retrieved from
478 [https://doi.org/10.1016/S0140-6736\(18\)33137-4](https://doi.org/10.1016/S0140-6736(18)33137-4). doi:10.1016/S0140-6736(18)33137-4
- 479 Hackshaw, A., Roughton, M., Forsyth, S., Monson, K., Reczko, K., Sainsbury, R., & Baum, M. (2011).
480 Long-Term Benefits of 5 Years of Tamoxifen: 10-Year Follow-Up of a Large Randomized Trial
481 in Women at Least 50 Years of Age With Early Breast Cancer. *Journal of Clinical Oncology*,
482 29(13), 1657-1663. Retrieved from <https://ascopubs.org/doi/abs/10.1200/JCO.2010.32.2933>.
483 doi:10.1200/jco.2010.32.2933
- 484 Hammar, N., Alfredsson, L., Rosen, M., Spetz, C. L., Kahan, T., & Ysberg, A. S. (2001). A national record
485 linkage to study acute myocardial infarction incidence and case fatality in Sweden. *Int J*
486 *Epidemiol*, 30 Suppl 1, S30-34. Retrieved from
487 <https://www.ncbi.nlm.nih.gov/pubmed/11759848>. doi:10.1093/ije/30.suppl_1.s30
- 488 Harris, E. E., Correa, C., Hwang, W. T., Liao, J., Litt, H. I., Ferrari, V. A., & Solin, L. J. (2006). Late cardiac
489 mortality and morbidity in early-stage breast cancer patients after breast-conservation
490 treatment. *Journal of clinical oncology : official journal of the American Society of Clinical*
491 *Oncology*, 24(25), 4100-4106. Retrieved from
492 <https://www.ncbi.nlm.nih.gov/pubmed/16908933>. doi:10.1200/JCO.2005.05.1037
- 493 Holm, J., Li, J., Darabi, H., Eklund, M., Eriksson, M., Humphreys, K., . . . Czene, K. (2016). Associations
494 of Breast Cancer Risk Prediction Tools With Tumor Characteristics and Metastasis. *Journal of*
495 *Clinical Oncology*, 34(3), 251-258. Retrieved from
496 <https://ascopubs.org/doi/abs/10.1200/JCO.2015.63.0624>. doi:10.1200/jco.2015.63.0624
- 497 Hooning, M. J., Botma, A., Aleman, B. M., Baaijens, M. H., Bartelink, H., Klijn, J. G., . . . van Leeuwen,
498 F. E. (2007). Long-term risk of cardiovascular disease in 10-year survivors of breast cancer.
499 *Journal of the National Cancer Institute*, 99(5), 365-375. Retrieved from
500 <http://www.ncbi.nlm.nih.gov/pubmed/17341728>
501 <http://jnci.oxfordjournals.org/content/99/5/365.full.pdf>. doi:10.1093/jnci/djk064
- 502 Khosrow-Khavar, F., Fillion, K. B., Bouganim, N., Suissa, S., & Azoulay, L. (2020). Aromatase Inhibitors
503 and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based
504 Cohort Study. *Circulation*, 141(7), 549-559. Retrieved from
505 <https://www.ncbi.nlm.nih.gov/pubmed/32065766>.
506 doi:10.1161/CIRCULATIONAHA.119.044750
- 507 Khouri, M. G., Douglas, P. S., Mackey, J. R., Martin, M., Scott, J. M., Scherrer-Crosbie, M., & Jones, L.
508 W. (2012). Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the
509 unresolved issues. *Circulation*, 126(23), 2749-2763. Retrieved from
510 <https://www.ncbi.nlm.nih.gov/pubmed/23212997>.
511 doi:10.1161/CIRCULATIONAHA.112.100560
- 512 Ludvigsson, J. F., Andersson, E., Ekblom, A., Feychting, M., Kim, J. L., Reuterwall, C., . . . Olausson, P. O.
513 (2011). External review and validation of the Swedish national inpatient register. *BMC Public*
514 *Health*, 11, 450. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/21658213>
515 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142234/pdf/1471-2458-11-450.pdf>.
516 doi:10.1186/1471-2458-11-450

- 517 Matthews, A., Stanway, S., Farmer, R. E., Strongman, H., Thomas, S., Lyon, A. R., . . . Bhaskaran, K.
518 (2018). Long term adjuvant endocrine therapy and risk of cardiovascular disease in female
519 breast cancer survivors: systematic review. *BMJ*, 363. doi:10.1136/BMJ.K3845
- 520 Papakonstantinou, A., Matikas, A., Bengtsson, N. O., Malmstrom, P., Hedayati, E., Steger, G., . . .
521 Bergh, J. (2020). Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and
522 trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER
523 trial. *Cancer*, 126(6), 1175-1182. Retrieved from
524 <https://www.ncbi.nlm.nih.gov/pubmed/31851385>. doi:10.1002/cncr.32653
- 525 Pinder, M. C., Duan, Z., Goodwin, J. S., Hortobagyi, G. N., & Giordano, S. H. (2007). Congestive heart
526 failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
527 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*,
528 25(25), 3808-3815. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/17664460>
529 <http://jco.ascopubs.org/content/25/25/3808.full.pdf>. doi:10.1200/JCO.2006.10.4976
- 530 Rosell, J., Nordenskjöld, B., Bengtsson, N.-O., Fornander, T., Hatschek, T., Lindman, H., . . .
531 Carstensen, J. (2013). Effects of adjuvant tamoxifen therapy on cardiac disease: results from
532 a randomized trial with long-term follow-up. *Breast cancer research and treatment*, 138(2),
533 467-473. Retrieved from <https://doi.org/10.1007/s10549-013-2457-6>. doi:10.1007/s10549-
534 013-2457-6
- 535 Schoormans, D., Pedersen, S. S., Dalton, S., Rottmann, N., & van de Poll-Franse, L. (2016).
536 Cardiovascular co-morbidity in cancer patients: the role of psychological distress. *Cardio-*
537 *Oncology*, 2(1), 9. Retrieved from <https://doi.org/10.1186/s40959-016-0019-x>.
538 doi:10.1186/s40959-016-0019-x
- 539 Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., . . . Early Breast Cancer
540 Trialists' Collaborative, G. (2017). Estimating the Risks of Breast Cancer Radiotherapy:
541 Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous
542 Randomized Trials. *Journal of clinical oncology : official journal of the American Society of*
543 *Clinical Oncology*, 35(15), 1641-1649. Retrieved from
544 <https://www.ncbi.nlm.nih.gov/pubmed/28319436>. doi:10.1200/JCO.2016.72.0722
- 545 Taylor, C. W., & Kirby, A. M. (2015). Cardiac Side-effects From Breast Cancer Radiotherapy. *Clin Oncol*
546 *(R Coll Radiol)*, 27(11), 621-629. Retrieved from
547 <https://www.ncbi.nlm.nih.gov/pubmed/26133462>. doi:10.1016/j.clon.2015.06.007
- 548 Taylor, C. W., Nisbet, A., McGale, P., Goldman, U., Darby, S. C., Hall, P., & Gagliardi, G. (2009). Cardiac
549 doses from Swedish breast cancer radiotherapy since the 1950s. *Radiother Oncol*, 90(1), 127-
550 135. doi:10.1016/j.radonc.2008.09.029
- 551 Thavendiranathan, P., Abdel-Qadir, H., Fischer, H. D., Camacho, X., Amir, E., Austin, P. C., & Lee, D. S.
552 (2016). Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in
553 Routine Clinical Practice: A Population-Based Cohort Study. *Journal of clinical oncology :*
554 *official journal of the American Society of Clinical Oncology*, 34(19), 2239-2246. Retrieved
555 from <https://www.ncbi.nlm.nih.gov/pubmed/27091709>. doi:10.1200/JCO.2015.65.1505
- 556 Wadsten, C., Wennstig, A. K., Garmo, H., Nilsson, G., Blomqvist, C., Holmberg, L., . . . Sund, M. (2018).
557 Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ. *Breast cancer*
558 *research and treatment*, 171(1), 95-101. doi:10.1007/s10549-018-4803-1
- 559 Wennstig, A.-K., Wadsten, C., Garmo, H., Fredriksson, I., Blomqvist, C., Holmberg, L., . . . Sund, M.
560 (2020). Long-term risk of ischemic heart disease after adjuvant radiotherapy in breast cancer:
561 results from a large population-based cohort. *Breast Cancer Research*, 22(1), 10. Retrieved
562 from <https://doi.org/10.1186/s13058-020-1249-2>. doi:10.1186/s13058-020-1249-2
- 563 Wigertz, A., Ahlgren, J., Holmqvist, M., Fornander, T., Adolfsson, J., Lindman, H., . . . Lambe, M.
564 (2012). Adherence and discontinuation of adjuvant hormonal therapy in breast cancer
565 patients: a population-based study. *Breast cancer research and treatment*, 133(1), 367-373.
566 Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/22286315>. doi:10.1007/s10549-012-
567 1961-4

568 Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: incidence,
569 pathogenesis, diagnosis, and management. *J Am Coll Cardiol*, 53(24), 2231-2247. Retrieved
570 from <https://www.ncbi.nlm.nih.gov/pubmed/19520246>. doi:10.1016/j.jacc.2009.02.050
571
572

573

574 **ONLINE SUPPLEMENTARY**

575

576 **Supplementary Table 1.** ICD codes used in the analyses

577 **Supplementary Table 2.** Cumulative incidence estimates of heart diseases in breast cancer

578 patients and age matched controls.

579 **Supplementary Table 3.** Hazard ratios for heart diseases by different adjuvant therapies and

580 time since diagnosis.

581 **Supplementary Table 4.** Hazard ratios for heart diseases by different adjuvant therapies,

582 excluding patients with a history of heart diseases.

583 **Supplementary Figure 1.** Flow chart of the data.

584 **Supplementary Figure 2.** Cumulative incidence of heart disease in breast cancer patients and matched

585 women.

586 Kaplan-Meier estimates of the cumulative risk of heart disease by time since diagnosis, in breast cancer

587 patients and matched women from the general population. BC: breast cancer; REF: reference women in

588 the matched controls from the general population; No.: number.

589 **Supplementary Table 1.** ICD codes used in the analyses.

590

Disease codes	ICD-10	ICD-9
Arrhythmia	I47, I48, I49	427
Atrial fibrillation	I48	427D
Tachycardia and other cardiac arrhythmias	I47, I49	427A-C, 427E-J
Heart failure	I50	428A, 428B, 428X
Ischemic heart disease	I20-I25	410-414
Myocardial infarction	I21,I22	410
Angina pectoris	I20	411B, 413, 414A
Hypertension	I10-I15	401-405
Tobacco abuse and Chronic Pulmonary Disease	J40-J47,J60-J67,F17, I278,I279,J684,J701,J703	490-496,500-505,416W,416X, 506E,508B,508W,305B

591

592

593

594

Abbreviations: ICD = International Classification of Diseases.

595
596
597
598

Supplementary Table 2. Cumulative incidence estimates of heart diseases in breast cancer patients and matched controls.

	Cumulative incidence, % (95% CI)					
	6 month	1 year	2 years	5 years	10 years	15 years
Arrhythmia						
Breast cancer	0.86 (0.68-1.08)	1.32 (1.10-1.59)	1.92 (1.65-2.25)	3.60 (3.21-4.04)	7.10 (6.52-7.73)	12.10 (11.12-13.16)
Matched control	0.33 (0.29-0.37)	0.60 (0.55-0.65)	1.15 (1.08-1.23)	2.78 (2.67-2.90)	5.91 (5.75-6.08)	9.60 (9.36-9.86)
Heart failure						
Breast cancer	0.20 (0.13-0.33)	0.45 (0.33-0.62)	0.75 (0.58-0.96)	1.46 (1.21-1.75)	2.93 (2.56-3.35)	5.59 (4.91-6.37)
Matched control	0.08 (0.06-0.10)	0.17 (0.14-0.20)	0.32 (0.29-0.36)	0.86 (0.80-0.93)	2.19 (2.09-2.29)	4.37 (4.19-4.56)
Ischemic heart disease						
Breast cancer	0.46 (0.33-0.63)	0.79 (0.62-1.00)	1.30 (1.08-1.57)	2.57 (2.24-2.95)	4.43 (3.97-4.93)	6.55 (5.85-7.34)
Matched control	0.23 (0.20-0.27)	0.54 (0.49-0.59)	1.07 (1.00-1.14)	2.45 (2.35-2.56)	4.68 (4.54-4.83)	7.01 (6.80-7.22)

599
600
601
602
603

Abbreviations: CI = confidence interval. Cumulative incidence estimates of heart diseases in all breast cancer patients (N = 8338) at different time-points following the index date (= date of diagnosis in breast cancer patients). Cumulative incidence estimates are obtained from Kaplan-Meier survival analyses.

604
605
606

Supplementary Table 3. Hazard ratios for heart diseases by different adjuvant therapies and time since diagnosis

Treatment variables	HR (95% CI) for Arrhythmia		HR (95% CI) for heart failure		HR (95% CI) for ischemic heart disease	
	<10y	>10y	<10y	>10y	<10y	>10y
Radiotherapy						
Right-sided	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Left-sided	0.94 (0.76-1.16)	0.83 (0.59-1.16)	1.02 (0.73-1.43)	0.92 (0.57-1.48)	1.10 (0.84-1.44)	1.32 (0.74-2.36)
Missing						
Chemotherapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Anthracyclines-based	1.02 (0.76-1.36)	1.00 (0.58-1.73)	1.84 (1.19-2.85)	2.31 (1.21-4.43)	1.09 (0.75-1.60)	1.18 (0.48-2.90)
Anthracyclines +Taxanes	0.75 (0.37-1.50)	0.75 (0.10-5.62)	5.08 (2.56-10.06)	0.00 (0.00-.)	1.28 (0.57-2.86)	0.00 (0.00-0.00)
CMF	1.74 (0.93-3.25)	0.72 (0.17-3.00)	1.33 (0.47-3.73)	0.69 (0.09-5.17)	0.67 (0.24-1.85)	0.92 (0.12-7.10)
Type unknown	1.18 (0.86-1.63)	1.09 (0.63-1.89)	1.75 (1.06-2.86)	1.38 (0.66-2.89)	1.47 (0.99-2.19)	1.31 (0.52-3.27)
Missing						
Hormone therapy						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Tamoxifen	1.02 (0.77-1.34)	1.10 (0.69-1.77)	0.76 (0.50-1.14)	1.06 (0.58-1.96)	0.82 (0.58-1.16)	1.36 (0.60-3.09)
Aromatase inhibitors	1.09 (0.81-1.48)	1.05 (0.56-1.96)	0.92 (0.60-1.41)	1.62 (0.76-3.46)	1.36 (0.93-1.97)	1.39 (0.48-4.06)
Type unknown	0.76 (0.49-1.20)	1.19 (0.68-2.09)	0.91 (0.49-1.69)	1.08 (0.51-2.29)	1.20 (0.75-1.92)	1.44 (0.54-3.83)
Missing						
Trastuzumab *						
No	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)	REF (1.00)
Yes	1.48 (0.90-2.43)	0.00 (0.00-0.00)	2.26 (1.20-4.27)	0.00 (0.00-0.00)	1.41 (0.76-2.59)	4.43 (0.39-49.76)
Missing						

607 Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox
608 proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios for model1 are adjusted for age and calendar period. Hazard ratios for model2 are multivariable adjusted
609 including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index
610 (0, 1, ≥2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), history of the specific heart disease, hypertension, chronic pulmonary disease and
611 tobacco abuse, and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

612
613**Supplementary Table 4.** Hazard ratios for heart diseases by different adjuvant therapies, excluding patients with a history of heart diseases

Treatment variables	Arrhythmia (N = 570)		Heart failure (N =243)		Ischemic heart disease (N =307)	
	N events	HR (95% CI)	N events	HR (95% CI)	N events	HR (95%)
Radiotherapy						
Right-sided	218	REF (1.00)	83	REF (1.00)	99	REF (1.00)
Left-sided	208	0.91 (0.75-1.10)	87	1.01 (0.74-1.36)	118	1.14 (0.87-1.49)
Missing	10		6		5	
Chemotherapy						
No	376	REF (1.00)	133	REF (1.00)	207	REF (1.00)
Anthracyclines-based	83	1.04 (0.79-1.38)	51	1.81 (1.22-2.70)	44	1.15 (0.78-1.68)
Anthracyclines +Taxanes	10	0.92 (0.47-1.79)	13	4.27 (2.18-8.35)	6	1.23 (0.51-2.94)
CMF	6	0.85 (0.37-1.95)	3	0.98 (0.30-3.17)	2	0.51 (0.13-2.11)
Type unknown	87	1.20 (0.89-1.61)	38	1.42 (0.91-2.21)	47	1.41 (0.95-2.10)
Missing	8		5		1	
Hormone therapy						
No	89	REF (1.00)	49	REF (1.00)	43	REF (1.00)
Tamoxifen	298	0.99 (0.76-1.27)	99	0.78 (0.54-1.12)	142	0.98 (0.68-1.42)
Aromatase inhibitors	119	1.06 (0.79-1.42)	61	1.03 (0.68-1.55)	85	1.48 (1.00-2.20)
Type unknown	56	0.91 (0.64-1.30)	29	0.91 (0.55-1.50)	36	1.17 (0.73-1.88)
Missing	8		5		1	
Trastuzumab *						
No	129	REF (1.00)	39	REF (1.00)	60	REF (1.00)
Yes	18	1.21 (0.71-2.04)	13	2.00 (1.02-3.92)	13	1.57 (0.82-2.99)
Missing	93		39		52	


614
615
616
617
618

Abbreviations: Total No. refers to the total number of patients. N events refers to the number of observed cases. HR = hazard ratio; CI = confidence interval. Hazard ratios are estimated from Cox proportional hazards models with time since diagnosis as underlying time scale. Hazard ratios are multivariable adjusted including age at diagnosis (years), year of diagnosis (2001/2002, 2003/2004, 2005/2006, 2007/2008), menopausal status (premenopausal, postmenopausal, unknown), Charlson comorbidity index (0, 1, ≥ 2), clinical stage (I, II, III, unknown), type of surgery (no, partial mastectomy, total mastectomy, unknown), and all treatment variables listed in the table. * Treatment-specific analysis of trastuzumab was restricted to patients diagnosed between 2005 and 2008.

619

620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655

Supplementary Figure 1. Flow chart of the data



656 **Supplementary Figure 2.** Cumulative incidence of heart diseases in breast cancer patients and matched reference individuals from the general
 657 population.

